Nutra Pharma Corp., a biotechnology company focused on developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has introduced a line of specialized contract research services targeted at the early-stage life science market.

“As a clinical stage company specializing in biologics, we understand and have cleared many of the hurdles that face emerging biotech companies,” stated Dr. Paul Reid, CEO of ReceptoPharm. “This knowledge, combined with our qualified drug production facility, allows us to leverage our expertise and capabilities by extending them to small and start-up biotechnology companies looking for cost effective outsourcing solutions for their clinical development projects.”

The services being introduced by ReceptoPharm include pre-production studies, contract manufacturing, United States and European Union regulatory support, and quality systems and GMP certification. The company can also prepare and sterile fill pharmaceutical products in its ISO class 5 cleanroom facilities for trials in the United States and the European Union.

“Opening ReceptoPharm’s GMP certified drug production facility to startup and smaller biopharmaceutical companies could not have come at a better time given the current state of the economy and the reduced level of financing available for many of these early-stage companies,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma. “By offering these services, at a much lower cost as compared to traditional contract research organizations, ReceptoPharm allows these life science firms to immediately continue innovating and developing medical technologies, instead of waiting for the economy to fully recover.”